# Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

> **NCT00028899** · PHASE1 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 47 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** asparaginase
- **DRUG:** cytarabine
- **DRUG:** gemtuzumab ozogamicin
- **DRUG:** mitoxantrone hydrochloride

## Key facts

- **NCT ID:** NCT00028899
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2006-09
- **Final completion:** 2012-03
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2014-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028899, "Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00028899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*